Keywords
How to Cite
Abstract
Introduction. The effect of chemotherapy is not limited to direct interaction between a given drug and tumor cells. In fact, cytostatic drugs induce a wide range of changes in the tumor immune microenvironment.
Aim. The research aims to analyze the expression profile of genes involved in immune regulation and inflammatory response; to evaluate the extent of inflammatory infiltration in high-grade serous ovarian carcinomas after the standard platinum-containing neoadjuvant chemotherapy; and to compare the results of molecular and morphological analysis with the clinical response to the treatment.
Materials and methods. The study involved 36 female patients who received a standard combination of paclitaxel and carboplatin as preoperative therapy. RNA from 25 primary tumor samples collected before the chemotherapy and from 28 postoperative residual tissues taken after the completion of neoadjuvant treatment were analyzed. The analysis was performed using the Human Inflammation and Immunity Transcriptome QIAseq Targeted RNA Panel (Qiagen, USA). In addition, lymphocytic infiltration was evaluated using the four-tier system (0 – no infiltration, 1 – minimal infiltration, 2 – focal occurrence, 3 – wide-spread occurrence). TP53 mutation types and levels of immune infiltration were compared in 107 primary and residual carcinomas. TP53 mutations were analyzed by the next-generation sequencing. 38 primary ovarian carcinomas were subjected to targeted DNA sequencing using the SeqCap EZ CNV/LOH Backbone Design panel. It allowed to analyze copy number alterations and build up chromosome instability profiles.
Results. The extent of lymphocytic infiltration observed before or after chemotherapy did not correlate with clinical response to paclitaxel and carboplatin therapy. CD3E, CXCL13, LYZ, CCL5, CD27, CD3D, IL2RG, CD2 and SELL genes were upregulated in chemonaive tumors with high content of lymphocytes. Increased expression of CCL18, CXCL13, CD27, LYZ, RUNX3 and SELL genes was observed in postsurgical tumor tissues with high lymphocyte infiltration. The frequency of increased lymphocyte infiltration was higher in chemonaive tumors with TP53 missense mutations compared to lesions with non-missense alterations. TP53 mutations had a stronger impact on the extent of infiltration in the context of chromosomal instability. All carcinomas with non-BRCAness profile and non-missense mutations had no or low infiltration (p = 0.03).
Conclusion. Targeted mRNA profiling of immune/inflammation-related genes allows identify carcinomas with high and low lymphocytic infiltration. The results of the study indicate a possible role of p53 in the tumor immune microenvironment.
References
Binnewies M, Roberts EW, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550. doi:10.1038/s41591-018-0014-x.
Man Y, Stojadinovic A, Mason J, et al. Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J Cancer. 2013;4:84-95. doi:10.7150/jca.5482.
Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015;5:16-8. doi:10.1158/2159-8290.CD-14-1397.
Goode EL, Block MS, Kalli KR, et al. Dose-response association of CD8+ Tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 2017;3:e173290. doi:10.1001/jamaoncol.2017.3290.
Mesnage SJL, Auguste A, Genestie C, et al. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann Oncol. 2017;28:651-657. doi:10.1093/annonc/mdw625.
Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690-714. doi:10.1016/j.ccell.2015.10.012.
Vankerckhoven A, Baert T, Riva M, et al. Type of chemotherapy has substantial effects on the immune system in ovarian cancer. Transl Oncol. 2021;14(6):101076. doi:10.1016/j.tranon.2021.101076.
Sokolenko AP, Gorodnova TV, Bizin IV, et al. Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients. Cancer Chemother Pharmacol. 2021;88(3):439-450. doi:10.1007/s00280-021-04301-6.
Sassen S, Schmalfeldt B, Avril N, et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol. 2007;38(6):926-34. doi:10.1016/j.humpath.2006.12.008.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8.
Yang M, Lu J, Zhang G, et al. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J Immunother Cancer. 2021;9(1):e001136. doi:10.1136/jitc-2020-001136.
Araujo JM, Gomez AC, Aguilar A, et al. Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. Sci Rep. 2018;8(1):4899. doi:10.1038/s41598-018-23099-7.
Cardoso AP, Pinto ML, Castro F, et al. The immunosuppressive and pro-tumor functions of CCL18 at the tumor microenvironment. Cytokine Growth Factor Rev. 2021;60:107-119. doi:10.1016/j.cytogfr.2021.03.005.
Milner JJ, Toma C, Yu B, et al. Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours. Nature. 2017;552(7684):253-7. doi:10.1038/nature24993.
Zumwalt TJ, Arnold M, Goel A, et al. Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration. Oncotarget. 2015;6(5):2981-91. doi:10.18632/oncotarget.3205.
Krisenko MO, Geahlen RL. Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer. Biochim Biophys Acta. 2015;1853(1):254-63. doi:10.1016/j.bbamcr.2014.10.022.
Fueyo J, Alonso MM, Parker Kerrigan BC, et al. Linking inflammation and cancer: the unexpected SYK world. Neuro Oncol. 2018;20(5):582-583. doi:10.1093/neuonc/noy036.
Elion DL, Cook RS. Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget. 2018;9(48):29007-29017. doi:10.18632/oncotarget.25626.
Shi Y, Riese DJ, Shen J. The Role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Front Pharmacol. 2020;11:574667. doi:10.3389/fphar.2020.574667.
Weberpals JI, Pugh TJ, Marco‐Casanova P, et al. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer. Cancer Med. 2021;10(9):3045-3058. doi:10.1002/cam4.3831.
Hwang HJ, Nam SK, Park H, et al. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer. J Pathol Transl Med. 2020;54(5):378-386. doi:10.4132/jptm.2020.06.01.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2023